| Literature DB >> 30086798 |
Alexis Rump1, Benjamin Becker2, Stefan Eder2, Andreas Lamkowski2, Michael Abend2, Matthias Port2.
Abstract
A wide spectrum of scenarios may lead to radiation incidents and the liberation of radioactive material. In the case of a terrorist attack by a "dirty bomb", there is a risk of mechanical and thermal trauma, external irradiation, superficial contamination and incorporation of radioactive material. The first treatment priority must be given to the care of trauma patients with life-threatening injuries, as the health effects of radiation occur with latency. Radionuclide incorporation will lead to a longer-lasting irradiation from inside the body, associated with a higher risk of stochastic radiation effects (e.g., occurrence of tumors) in the long run. It must be expected that victims with potentially incorporated radionuclides will far outnumber trauma patients. The elimination of radionuclides can be enhanced by the administration of decorporation agents such as (Ca) Diethylenetriaminepentaacetic acid (DTPA) or Prussian blue, reducing the radiological burden of the body. There is still no consensus whether decorporation treatment should be started immediately based only on a suspicion of radionuclide incorporation ("urgent approach") or if the results of internal dosimetry confirming the necessity of a treatment should be awaited, accepting the delay caused by the measurements and computations ("precautionary approach"). As the therapeutic effectiveness may be substantially decreased if treatment initiation is delayed only by several days, depending on the radionuclide, the physicochemical properties of the compounds involved and the route of absorption, we favor an "urgent approach" from a medical point of view. In doubt, it seems justified to treat victims by precaution, as the adverse effects of the medication seem minimal. However, in the case of a high number of victims, an "urgent treatment approach" may require a large number of daily doses of antidotes, and therefore, adequate investments in preparedness and antidote stockpiling are necessary.Entities:
Keywords: Combined injuries; Decorporation therapy; Dirty bomb; Medical NRBC protection; Radiological emergency; Radionuclide incorporation
Mesh:
Substances:
Year: 2018 PMID: 30086798 PMCID: PMC6080556 DOI: 10.1186/s40779-018-0174-5
Source DB: PubMed Journal: Mil Med Res ISSN: 2054-9369
Radionuclides of concern that might be used in the construction of a “dirty bomb”. [9] Source for physical and effective half-life values [10]
| Item | Am-241 | Cf-252 | Co-60 | Cs-137 | I-131 | Ir-192 | Pu-238 | Pu-239 | Ra-226 | Sr-90 | U-235 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Radiation emitted | α, γ | α, n | β, γ | β, γ | β, γ | β, γ | α | α | α, γ | β | α, γ |
| Physical half-life | 432 a | 2.65 a | 5.3 a | 30 a | 8 d | 73.8 d | 87.7 a | 24 103 a | 1600 a | 28.2 a | 7 × 108 a |
| Effective half-life | 45 a | 2.5 a | 1.6 a | 109 d | 7.5 d | – | 50 a | 50 a | 44 a | 4.6 a | 15 d |
“-” Not available; a: years; d: days
Fig. 1The protective equipment of the medical task force for nuclear and radiological emergencies of the Bundeswehr Institute of Radiobiology. Light equipment is sufficient to protect against radioactive contamination but permits good patient care
Fig. 2The medical task force for nuclear and radiological emergencies of the Bundeswehr Institute of Radiobiology in action during the exercise Precise Care 2017
Fig. 3The different steps of internal dosimetry computations using IMBA software. a Radionuclide selection; b Computation of the initial activity intake from the measured activity; c Representation of the time course of activity in the body; d Computation of the committed effective dose from the initial activity intake. IMBA. Integrated Modules for Bioassay Analysis
The two decorporation agents that are essential for nuclear/radiological emergencies and the radionuclides whose excretion can be enhanced
| Antidote | Radionuclides |
|---|---|
| (Ca)DTPA | Americium, Californium, Cerium, Chrome, Cobalt, Curium, Erbium, Europium, Iron, Gallium, Iridium, Lanthanum, Manganese, Plutonium, Praseodymium, Promethium, Ruthenium, Samarium, Scandium, Thorium, Ytterbium, Yttrium, Zinc, Zirconium; Mixture of fission products |
| Prussian blue | Cesium, Thallium, Indium; Mixture of fission products |
Fig. 4Time course of radioactivity in the central compartment [44] (blood, extracellular space) emanating from a wound contaminated with 37 kBq (1 μCi) of plutonium-239 as a soluble compound. Activity falls to low values after approximately 10 days. The decorporation agent (Ca) DTPA is distributed mainly in the extracellular space, where it can bind plutonium. Thus, treatment must start within 10 days to be highly effective (“therapeutic window”)
Fig. 5Efficacy of a decorporation treatment using (Ca)DTPA or Prussian blue after the acute inhalation of a poorly soluble compound containing plutonium-239 [45] (e.g., plutonium oxide) or a soluble compound containing cesium-137 (e.g., cesium chloride), depending on the time after the incident the treatment is initiated. Treatment duration is assumed to be 90 days. Efficacy = 1 – (dose with treatment / dose without treatment)